MeSH D005776 - gaucher disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Eliglustat | Eliglustat | 2021-12-27 | |||
| Johnson & Johnson | Miglustat | Zavesca | 2002-11-20 | |||
| Sanofi | Eliglustat | Cerdelga | 2022-04-29 | 2014-08-19 | ||
| Imiglucerase | Cerezyme | 1994-05-23 | ||||
| Pfizer | Taliglucerase alfa | Elelyso | 2012-05-01 | |||
| Takeda | Velaglucerase alfa | Vpriv | 2010-02-26 | |||
| Dr Reddys Laboratories | Eliglustat | Eliglustat | 2022-08-17 | |||
| Breckenridge Pharmaceutical | Miglustat | Miglustat | 2022-02-03 | |||
| ANI Pharmaceuticals | Miglustat | Miglustat | 2018-04-17 | |||
| Aizant Drug Research Solutions | Eliglustat | Eliglustat | 2021-09-08 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
93%13/14
Phase 2
48%11/23
Phase 3
83%15/18
Approved: 10Overall Success rate: 37%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use